EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effects of Inhibitors of the Activity of the Circulating Renin–Angiotensin System on the Growth and Proliferation of Endometrial Cancer Cells

Sarah J Delforce, Riazuddin Mohammed, Tess L Symington iD, Yu Wang, Nicole M Verrills, Eugenie R Lumbers, Kirsty G Pringle iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms262210968 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Sarah J Delforce und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine and Public Health, College of Health, Medicine and Wellbeing, University of Newcastle, Newcastle, NSW 2308, Australia. Hauptthemen laut MEDLINE: Renin-Angiotensin System, Endometrial Neoplasms, Cell Proliferation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: John Hunter Charitable Trust, Hunter Medical Research Institute, John Hunter Hospital Charitable Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Endometrial cancers increase expression of the renin–angiotensin system (RAS). This study aimed to determine if inhibiting the RAS would reduce the viability and proliferation of endometrial cancer cells. The expression of RAS genes was measured in three endometrial epithelial adenocarcinoma cell lines (Ishikawa, HEC-1-A, AN3CA). Ishikawa cells had the highest expression of REN, ACE, and AGTR1 mRNA. AGT mRNA and protein levels were most abundant in HEC-1-A cells. We then determined the effects of drugs that inhibit the action of renin (VTP-27999 and aliskiren) or angiotensin-converting enzyme (perindoprilat) or block the angiotensin II type 1 receptor (losartan and telmisartan). Overall, VTP-27999, aliskiren, perindoprilat, and losartan had minimal effects on cell viability in all three cell lines, and combinations of these drugs did not have any effect. Telmisartan (a dual angiotensin receptor blocker and PPAR-γ agonist) significantly reduced the viability of all three cell lines and reduced the proliferation of both Ishikawa and AN3CA cells. Telmisartan was more effective than troglitazone (PPAR-γ agonist) in Ishikawa and HEC-1-A cells. RAS inhibitors were most effective in Ishikawa cells, which had the highest levels of RAS expression. Therefore, levels of RAS expression in endometrial cancers might indicate the potential efficacy of RAS drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Renin-Angiotensin SystemEndometrial NeoplasmsCell ProliferationHumansFemaleCell Line, TumorTelmisartanAngiotensin-Converting Enzyme InhibitorsReceptor, Angiotensin, Type 1Cell SurvivalReninAngiotensin II Type 1 Receptor BlockersGene Expression Regulation, NeoplasticAmidesFumaratesLosartanRenin Inhibitors

Stichwörter der Autor:innen

ACE inhibitorsangiotensin receptor blockersendometrial cancerrenin inhibitorsrenin–angiotensin system

Substanzen

TelmisartanAngiotensin-Converting Enzyme InhibitorsReceptor, Angiotensin, Type 1ReninAngiotensin II Type 1 Receptor BlockersAmidesFumaratesLosartanRenin Inhibitorsaliskiren

Autor:innen und Institutionen

  • School of Medicine and Public Health, College of Health, Medicine and Wellbeing, University of Newcastle, Newcastle, NSW 2308, Australia.
  • School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Newcastle, NSW 2308, Australia.
  • Cancer Detection and Therapy Program, Hunter Medical Research Institute, New Lambton Heights, NSW 2305, Australia.
  • Women's Health Research Program, Hunter Medical Research Institute, New Lambton Heights, NSW 2305, Australia.
  • R&D, Beroni Group Ltd., Sydney, NSW 2000, Australia.

ORCID-Profile: Tess L Symington, Kirsty G Pringle

Förderung

  • John Hunter Charitable Trust
  • Hunter Medical Research Institute
  • John Hunter Hospital Charitable Trust
  • ARC Future Fellowships

Zitieren

APA

Delforce, S. J., Mohammed, R., Symington, T. L., Wang, Y., Verrills, N. M., Lumbers, E. R., & Pringle, K. G. (2025). Effects of Inhibitors of the Activity of the Circulating Renin–Angiotensin System on the Growth and Proliferation of Endometrial Cancer Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262210968

Vancouver

Delforce SJ, Mohammed R, Symington TL, Wang Y, Verrills NM, Lumbers ER, et al. Effects of Inhibitors of the Activity of the Circulating Renin–Angiotensin System on the Growth and Proliferation of Endometrial Cancer Cells. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262210968

BibTeX
@article{Delforce2025,
  author = {Delforce, Sarah J and Mohammed, Riazuddin and Symington, Tess L and Wang, Yu and Verrills, Nicole M and Lumbers, Eugenie R and Pringle, Kirsty G},
  title = {Effects of Inhibitors of the Activity of the Circulating Renin–Angiotensin System on the Growth and Proliferation of Endometrial Cancer Cells},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms262210968}
}
Kostenlos starten →